US2008161277A1PendingUtilityA1
Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
Est. expiryJun 11, 2018(expired)· nominal 20-yr term from priority
Inventors:Fernand Labrie
A61P 3/04A61P 43/00A61P 9/00A61P 5/26A61P 5/24A61P 9/10A61P 5/48A61P 3/10A61P 25/00A61P 35/00A61P 25/28A61P 15/10A61P 13/08A61P 17/00A61P 15/02A61P 19/10A61P 13/00A61P 15/12A61P 15/18A61P 15/00A61P 15/08A61P 21/00A61K 31/568A61K 31/565A61K 31/57A61K 31/5685
63
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Androst-5-ene-3β,17β diol is used to treat or reduce the likelihood of acquiring osteoporosis or menopausal symptoms, or other diseases affected by estrogen receptor activity, and for conditions which respond well to DHEA treatment, but where a higher ratio of estrogenic to androgenic effects is desired. Combination therapies are included, as are kits and pharmaceutical compositions for providing the active ingredients of claimed methods and combinations.
Claims
exact text as granted — not AI-modified1 - 27 . (canceled)
28 . A method of reducing the likelihood of acquiring an indication selected from the group consisting of symptoms of menopause, vaginal atrophy, hypogonadism, osteoporosis, urinary incontinence, uterine cancer and ovarian cancer comprising administering to a patient in need of said reduction androst-5-ene-3β 17β-diol, or a prodrug thereof.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.